Cerenome, Inc. (CNSY)
1.93
+0.14
(+7.82%)
USD |
NASDAQ |
Oct 09, 16:00
1.91
-0.02
(-1.04%)
After-Hours: 19:12
Cerenome Enterprise Value : 4.542M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 4.542M |
| October 07, 2026 | 3.409M |
| October 06, 2026 | 3.080M |
| October 05, 2026 | 2.861M |
| October 02, 2026 | 3.153M |
| October 01, 2026 | 4.469M |
| September 30, 2026 | 5.127M |
| September 29, 2026 | 5.054M |
| September 28, 2026 | 6.223M |
| September 25, 2026 | 6.004M |
| September 24, 2026 | 5.127M |
| September 23, 2026 | 5.712M |
| September 22, 2026 | 6.296M |
| September 21, 2026 | 5.346M |
| September 18, 2026 | 6.296M |
| September 17, 2026 | 6.296M |
| September 16, 2026 | 6.369M |
| September 15, 2026 | 6.954M |
| September 14, 2026 | 7.320M |
| September 11, 2026 | 8.453M |
| September 10, 2026 | 8.928M |
| September 09, 2026 | 9.659M |
| September 08, 2026 | 11.19M |
| September 04, 2026 | 11.60M |
| September 03, 2026 | 13.24M |
| Date | Value |
|---|---|
| September 02, 2026 | 12.95M |
| September 01, 2026 | 11.27M |
| August 31, 2026 | 12.07M |
| August 28, 2026 | 13.75M |
| August 27, 2026 | 14.12M |
| August 26, 2026 | 13.53M |
| August 25, 2026 | 14.01M |
| August 24, 2026 | 13.09M |
| August 21, 2026 | 13.90M |
| August 20, 2026 | 13.39M |
| August 19, 2026 | 14.78M |
| August 18, 2026 | 13.97M |
| August 17, 2026 | 14.85M |
| August 14, 2026 | 18.36M |
| August 13, 2026 | 18.50M |
| August 12, 2026 | 18.50M |
| August 11, 2026 | 19.45M |
| August 10, 2026 | 19.53M |
| August 07, 2026 | 19.45M |
| August 06, 2026 | 19.67M |
| August 05, 2026 | 20.04M |
| August 04, 2026 | 20.40M |
| August 03, 2026 | 17.19M |
| July 31, 2026 | 19.75M |
| July 30, 2026 | 18.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ernexa Therapeutics, Inc. | -1.765M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 1.982B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.006M |
| Revenue (Quarterly) | 0.411M |
| Total Expenses (Quarterly) | 9.417M |
| EPS Diluted (Quarterly) | -1.305 |
| Gross Profit Margin (Quarterly) | 63.26% |
| Profit Margin (Quarterly) | -2.19K% |
| Earnings Yield | -228.5% |
| Normalized Earnings Yield | -228.49 |